Tuesday, October 4, 2022


Biotechnology News Magazine

BioZorb 3D Bioabsorbable Marker: Published Study Show a Safe Adjunct to Breast-Conserving Surgery that May Benefit Radiation Oncologists, Surgeons and Patients

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

February 2, 2021

BioZorb 3D bioabsorbable marker (Hologic) when used as an adjunct to breast-conserving surgery, demonstrates safety according to new research  [i] Published online in the Annals of Surgical Oncology, the BioZorb® Registry is the first large, multi-center study to report 24-month outcomes following implantation of the marker as part of breast-conserving surgery.

BioZorb 3D bioabsorbable marker is a 3D implantable marker consisting of a spiral, bioabsorbable framework embedded with six permanent, titanium clips designed to precisely mark the surgical excision site. BioZorb 3D bioabsorbable marker is designed to absorb into the body over a year or more, the BioZorb marker is used in breast-conserving surgery and provides 3-dimensional targeting for radiation therapy.

“This study reinforces the existing body of research supporting the BioZorb 3D bioabsorbable marker on a national scale, strengthening the case that it is a helpful adjunct for breast-conserving surgeries, particularly those requiring post-procedure radiation therapy,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions.

Radiation oncologists participating in the study reported the BioZorb device often aided in targeting for tumor bed boost and accelerated partial breast irradiation (APBI).i

“Radiation oncologists are trained to target seromas, but newer oncoplastic surgical techniques can rearrange tissues, making traditional methods of defining the tumor bed challenging,” said William H. Hall III, MD, co-author and radiation oncologist with Bellingham Radiation Oncology in Bellingham, WA. “In my experience, the BioZorb marker allows for more accurate delineation of the lumpectomy cavity and can contribute to smaller planning target volumes, reducing irradiation of normal tissue.”

Surgeons reported their primary motives for using the BioZorb 3D bioabsorbable marker were as a communications tool for radiation targeting, as well as enhancing the cosmetic outcome.i

Patients and surgeons indicated the BioZorb marker yielded a significant cosmetic benefit, with 90% or more of patients reporting good-to-excellent long-term cosmetic outcomes with low adverse effects.

“As more patients enjoy long-term survival following breast-conserving surgery, cosmetic results gain increasing clinical importance, particularly given the correlation to quality of life,” said Cary S. Kaufman, MD, FACS, lead author and surgeon at Bellingham Regional Breast Center in Bellingham, WA. “I’ve seen in my own patients that the BioZorb marker has a major cosmetic benefit, and this registry study replicates those results on a national scale. It is my belief that the BioZorb marker is clearly a valuable addition to a surgeon’s toolkit to provide comprehensive, patient-focused care.”


[i] Kaufman CS, Cross MJ, Barone JL, Dekhne NS, Devisetty K, Dilworth JT, Edmonson DA, Eladoumikdachi FG, Gass JS, Hall WH 3rd, Hong RL, Kuske RR, Patton BJ, Perelson C, Phillips RF, Smith AB, Smith LA, Tafra L, Lebovic GS. A Three-Dimensional Bioabsorbable Tissue Marker for Volume Replacement and Radiation Planning: A Multicenter Study of Surgical and Patient-Reported Outcomes for 818 Patients with Breast Cancer. Ann Surg Oncol. 2020 Nov 21. doi: 10.1245/s10434-020-09271-2. Epub ahead of print. PMID: 33221977.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine